These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30301554)

  • 1. Bevacizumab: Is the lower the better for glioblastoma patients in progression?
    Sirven-Villaros L; Bourg V; Suissa L; Mondot L; Almairac F; Fontaine D; Paquis P; Burel-VandenBos F; Frenay M; Thomas P; Lebrun-Frenay C
    Bull Cancer; 2018 Dec; 105(12):1135-1146. PubMed ID: 30301554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.
    Eryılmaz MK; Mutlu H; Yalçin Müsri F; Salim DK; Tazegül G; Coşkun HŞ
    J Oncol Pharm Pract; 2017 Jul; 23(5):392-395. PubMed ID: 27105898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
    Hertenstein A; Hielscher T; Menn O; Wiestler B; Winkler F; Platten M; Wick W; Wick A
    J Neurooncol; 2016 Sep; 129(3):533-539. PubMed ID: 27422128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    Blumenthal DT; Mendel L; Bokstein F
    J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing bevacizumab dosing in glioblastoma: less is more.
    Ajlan A; Thomas P; Albakr A; Nagpal S; Recht L
    J Neurooncol; 2017 Oct; 135(1):99-105. PubMed ID: 28667595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
    Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
    Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
    J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab.
    Liau CT; Chou WC; Wei KC; Chang CN; Toh CH; Jung SM
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e8-e14. PubMed ID: 28792121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of bevacizumab monotherapy on progression free survival in recurrent glioblastoma].
    Czigléczki G; Sinkó D; Benkő Z; Bagó A; Fedorcsák I; Sipos L
    Ideggyogy Sz; 2019 May; 72(5-6):153-158. PubMed ID: 31241258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
    Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H
    Cancer; 2017 Sep; 123(18):3576-3582. PubMed ID: 28678383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
    Tipping M; Eickhoff J; Ian Robins H
    J Clin Neurosci; 2017 Oct; 44():101-106. PubMed ID: 28711289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
    J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
    Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
    Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.